Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAL801CL (Epinastine) vs Ketotifen in Pediatric Perennial Allergic Rhinitis
NCT02182544Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2001
- Primary completion
- Dec 2001
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of epinastine in perennial allergic rhinitis (PAR), sponsored by Boehringer Ingelheim. Started Jun 2001; status: completed.
02
Drugs
epinastine
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT02182544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182544.